Back to News
Market Impact: 0.2
Path Fertility Awarded $2 Million NIH Grant to Develop Epigenetic Test for Severe Male Infertility and Associated Cancer Risk
Source: Newswire
Healthcare & BiotechTechnology & Innovation
At ASRM 2026, the company presented data indicating sperm epigenetics predicts IUI success across clinics and physicians. It also reported that sperm-derived cell-free DNA predicts sperm retrieval outcomes in men with azoospermia; the article provides no numerical results or clinical validation details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
More News
- A shock in Brazil sends stocks plunging, while neoclouds take another hit
- Anthropic’s risk factors include the end of humanity, a feud with the Pentagon, and CEO Dario Amodei’s reputation
- Elon Musk warns more than 200 AI cloud companies face ‘guppy-level death’ as the AI boom runs into a debt crisis
- Anthropic Files for IPO While Warning of ‘Catastrophic’ AI Risks
- Anthropic’s IPO filing shows explosive growth, risks and staggering costs
- Meta, SpaceX, Anthropic stoke the AI funding frenzy. What it means for our stocks